ANDROMEDA-SHOCK-2 Trial
Enrolling By Invitation
18-99 years
All
Phase
N/A
25 participants needed
1 Location
Brief description of study
Septic shock is a disease of the circulatory system representing a complication of serious infections, and is associated with a very high mortality, since around 1/3 of patients with this condition die. This disease produces a series of alterations in the body, including failure of the heart, kidneys, liver, among others. The fundamental problem is poor oxygenation of the tissues. From a hemodynamic point of view, low blood pressure is characteristic and the longer it is maintained, the greater the risk of mortality.
The goal of this study is to test if a capillary refill time or CRT-targeted resuscitation based on clinical hemodynamic phenotyping can improve a hierarchical clinical outcome - mortality, time to cessation of vital support, and length of hospital stay, all within 28 days - in septic shock patients as compared to usual care.
Patients will septic shock are routinely admitted to the intensive care unit at the Hospital of the University of Pennsylvania and its satellite hospitals. Patients who fulfill the inclusion criteria of the diagnosis of septic shock will be reported by the medical record alert system to the Principal Investigator for enrollment decision. The expected enrollment is not to exceed two enrollments in a month, which is feasible given the number of patients with diagnosed sepsis who are admitted each month is 50.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: septic shock
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 849830
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
